Patents by Inventor John Desmond Walsh

John Desmond Walsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bioimplant formulation comprising lecithin and stearin
    Patent number: 8052982
    Abstract: Pharmaceutical and/or veterinary formulation containing about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent comprising lecithin and an organic salt, and the balance stearin.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: November 8, 2011
    Assignee: Peptech Animal Health PTY Limited
    Inventors: Timothy Elliott Trigg, John Desmond Walsh, Deborah Ann Rathjen
  • Sustained peptide-release formulation
    Patent number: 7309689
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: December 18, 2007
    Assignee: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Bioimplant formulation
    Patent number: 6913761
    Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-foaming agent and the balance stearin. Such formulations provided release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: July 5, 2005
    Assignee: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Deborah Ann Rathjen
  • Sustained peptide-release formulation
    Publication number: 20040180832
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Application
    Filed: March 25, 2004
    Publication date: September 16, 2004
    Applicant: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Sustained peptide-release formulation
    Patent number: 6777386
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: August 17, 2004
    Assignee: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Sustained peptide-release formulation
    Publication number: 20020052320
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15 % (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5 % (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Application
    Filed: November 26, 2001
    Publication date: May 2, 2002
    Applicant: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Sustained GnRH peptide-release formulation
    Patent number: 6337318
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: January 8, 2002
    Assignee: Peptech, Ltd.
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober